The effects of enoxaparin in treatment of esophageal cancer

The effect of addition of enoxaparin to neoadjuvant chemoradiation of esophageal cancer on the clinical and pathologic response and value of post-chemoradiation findings in prediction of complete pathologic response

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016070628814N1

Enrollment

100

Registered

2016-07-17

Start date

2016-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Malignant neoplasm of oesophagus. Condition 2: Follow-up examination after combined treatment for malignant neoplasm. Malignant neoplasm of oesophagus Follow-up examination after combined treatment for malignant neoplasm

Interventions

Intervention 1: In the intervention group, patients are going to receive subcutaneous enoxaparin (40 mg) daily concurrent with chemo-radiotherapy. Intervention 2: chemo-radiotherapy.

Treatment - Drugs

Treatment - Other

In the intervention group, patients are going to receive subcutaneous enoxaparin (40 mg) daily concurrent with chemo-radiotherapy.

chemo-radiotherapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria are definitive diagnoses of esophageal cancer by oncologist and pathological evaluation, non-metastatic esophageal cancer, patient who are candidate for chemo-radiation treatment, pathological report of SCC, normal CBC, normal kidney function test, normal liver function test, normal FBS. Exclusion criteria are previous history of chest wall radiotherapy, previous history of chemotherapy, past medical history of HTN, DM, renal failure and liver failure, pathological report of adenocarcinoma or small cell carcinoma, neoplasm of other organs, discontent for the study, inability to do daily radiotherapy, unwillingness to esophagectomy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Clinical responce. Timepoint: 4-6 weeks after complete of combined treatment. Method of measurement: according to endoscopic findings (no lesion, primary lesion or became smaller less than 50%of primary lesion, become smaller more than 50% of primary lesion).;Pathologic responce. Timepoint: 4-6weeks after complete of treatment. Method of measurement: according to pathologic findigs of esophagous specimen (complete Vs incompelet).;R staging (residual of tumor). Timepoint: intraoperative of eosophagectomy. Method of measurement: according to surgeon findigs when eosophagectomy is done (gross residue, microscopic residue, without residue).	—

Measure

Time frame

Clinical responce. Timepoint: 4-6 weeks after complete of combined treatment. Method of measurement: according to endoscopic findings (no lesion, primary lesion or became smaller less than 50%of primary lesion, become smaller more than 50% of primary lesion).;Pathologic responce. Timepoint: 4-6weeks after complete of treatment. Method of measurement: according to pathologic findigs of esophagous specimen (complete Vs incompelet).;R staging (residual of tumor). Timepoint: intraoperative of eosophagectomy. Method of measurement: according to surgeon findigs when eosophagectomy is done (gross residue, microscopic residue, without residue).

—

Secondary

Measure	Time frame
Heparin induced thrombocytopenia. Timepoint: before prescription of any course of chemotherapy. Method of measurement: according to CBC.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholami, Arezoo

Radiation Oncology Department, Faculty of Medicine, Mashhad University of Medical Sciences

gholamia931@mums.ac.ir+98 518426936

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026